Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies
AbstractApoptosis, the process of programmed cell death, occurs normally during development and aging. Members of the B-cell lymphoma 2 (BCL2) family of proteins are central regulators of apoptosis, and resistance to apoptosis is one of the hallmarks of cancer. Targeting the apoptotic pathway via BCL2 inhibitors has been considered a promising treatment strategy in the past decade. Initial efforts with small molecule BH3 mimetics such as ABT-737 and ABT-263 (navitoclax) pioneered the development of the first-in-class Food and Drug Administration (FDA)-approved oral BCL2 inhibitor, venetoclax. Venetoclax was approved for the treatment of chronic lymphocytic leukemia and acute myeloid leukemia, and is now being studied in a number of hematologic malignancies. Several other inhibitors targeting different BCL2 family members are now in early stages of development.
Authors: Wang X, Wen Y, Xue L, Lu R, Tang H, Gao N, Zhang J, Xue Q PMID: 31961109 [PubMed - as supplied by publisher]
Authors: Wang P, Xue L, Wang L, Tang H, Lv C, Xue Q PMID: 31961108 [PubMed - as supplied by publisher]
Authors: Wu G, Ke J, Wang J, Zhu X, Xiong S PMID: 31961113 [PubMed - as supplied by publisher]
We present an 81-year-old male patient with high-risk non-nodal leukemic MCL, with exorbitant leukocytosis/lymphocytosis, and an unprecedented finding of a morphology mimicking adult T cell leukemia, given the presence of flower cells in peripheral blood. This is the only case of MCL and one of the few B-cell lymphomas with this atypical morphology ever reported. Relevant literature hypotheses about the origin of this morphology are discussed
Anterior-dominant prostate cancer is harder to detect and presents with higher prostate-specific antigen (PSA) levels than prostate cancer in other locations, according to a database study.Reuters Health Information
When the patriarch of a Boston-area family was diagnosed with stage 3 pancreatic cancer, the family was told he needed to start treatment immediately.
In conclusion, we identified a novel Bcl-2 inhibitor by QSAR screening, which exerted significant cytotoxic activity in breast cancer cells through inducing mitochondria-mediated apoptosis. Introduction Apoptosis is a process of cellular suicide through which unwanted or unhealthy cells are eliminated during organism development or cellular stress (Reed, 2002; Fernald and Kurokawa, 2013). Deregulated apoptosis is a characteristic of cancers (Doi et al., 2012; Roizen, 2012). The B-cell lymphoma-2 (Bcl-2) family is composed of pro- and anti-apoptotic proteins, plays pivotal role in the mitochondrial pathway of apoptosi...
Yi He†, Wenyong Long† and Qing Liu* Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China Super-enhancers (SEs) refer to large clusters of enhancers that drive gene expressions. Recent data has provided novel insights in elucidating the roles of SEs in many diseases, including cancer. Many mechanisms involved in tumorigenesis and progression, ranging from internal gene mutation and rearrangement to external damage and inducement, have been demonstrated to be highly associated with SEs. Moreover, translocation, formation, deletion, or duplication of SEs themselves co...
Author Affiliations open 1 McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, Canada 2 Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain 3 Universitat Pompeu Fabra (UPF), Barcelona, Spain 4 CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain 5 School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada 6 Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA 7 Department of Economics, Brigham Young University, Provo, Utah, USA 8 Population Studies Division, Health Canada, Ottawa, Cana...
This article summarizes the milestones in the development of venetoclax leading to this first approval for CLL.